A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation |
| |
Authors: | Beckingham I J; Woodrow G; Hinwood M; Rigg K M; Morgan A G; Burden R P; Broughton-Pipkin F |
| |
Institution: | 1Department of Surgery City Hospital, Nottingham
2Department of Renal Medicine City Hospital, Nottingham
3Department of Obstetrics and Gynaecology, University Hospital Nottingham |
| |
Abstract: | BACKGROUND: Erythrocytosis is a common complication of renal transplantationwith an incidence of up to 17%. It is associated with an increasedrisk of complications due to thromboembolic events and has traditionallybeen treated by intermittent venesection. More recently, angiotensin-convertingenzyme inhibitors have been shown to cause a fall in haematocritin a number of groups of subjects and some uncontrolled studieshave shown these drugs to be of possible therapeutic benefitin post renal transplant erythrocytosis. METHODS: We performed a randomized double-blind placebo-controlled studyin 25 patients with post-transplant erythrocytosis. Subjectsreceived either 2.5 mg of enalapril daily or a placebo for 4months and all patients completed the study period without anyserious adverse effects. RESULTS: Haematocrit fell from 52.7 (±SEM 0.7) to 47.1 (±1.8) at 1 month and 46.1 (± 1.2) after 4 months in patientsreceiving enalapril, with no change in the placebo group (P=0.004).We did not demonstrate any change in serum erythropoietin ineither group. CONCLUSION: Angiotensin-converting enzyme inhibitors are a safe and effectiveform of treatment for erythrocytosis developing after renaltransplantation. The mechanism of action, however, is not mediatedby changes in erythropoietin production and remains uncertain. |
| |
Keywords: | placebo-controlled erythrocytosis renal transplantation |
本文献已被 Oxford 等数据库收录! |